Project ALS is pleased to welcome four pre-eminent scientists to its Research Advisory Board. Since inception, the Project ALS Research Advisory Board has led an aggressive, effective offensive against ALS, setting the agenda for the entire ALS research field. Now, with the addition of new leaders from Harvard, King’s College London, MIT, and Novartis, Project ALS is more poised than ever to recognize, and act on, bold new ideas toward the first effective treatments for ALS. New members include:
Juan Burrone, Ph.D. – Dr. Burrone is Professor of Development Neurophysiology at King’s College London. His expertise is brain circuitry, specifically synaptic transmission, or how neurons communicate with one another. He says: “I am thrilled to be part of this remarkable endeavour and eager to help Project ALS continue with its policy of fostering cutting-edge research in the hope of discovering new and better therapeutic strategies for treating ALS.”
Alfred Goldberg, Ph.D. – Dr. Goldberg is a foremost expert on cell biology. He earned his A.B. in 1963 and his Ph.D. in 1968 from Harvard University and was appointed an Assistant Professor at Harvard Medical School in 1969, immediately following one year as an Instructor. Dr. Goldberg has been a Professor at Harvard Medical School since 1977. He says: “I’m looking forward to working with you all and to advancing our understanding and treatments of ALS.”
H. Robert Horvitz, Ph.D. – Dr. Horvitz was awarded the 2002 Nobel Prize in Physiology or Medicine for his pioneering work on the role of programmed cell death as it relates to human disease. He is Professor of Biology at the Massachusetts Institute of Technology, where he is also a member of the McGovern Institute for Brain Research. Dr. Horvitz’s father died of ALS. He says: “I am delighted to be joining this outstanding group to help with the efforts of Project A.L.S.”
Jeffrey Porter, Ph.D. – Dr. Porter is the Head of Developmental and Molecular Pathways for the Novartis Institutes for BioMedical Research. Among his duties is the task of developing biological pathways research. Novartis’s efforts have led to many publications and the discovery of targets that have the potential to help patients in need. Previously, as a scientist with Cambridge based biotech Curis, Dr. Porter was instrumental in the studies that led Project A.L.S. researchers to differentiate embryonic stem cells in to bone fide motor neurons.